Spark Therapeutics' eye drug succeeds in study

[October 05, 2015]  (Reuters) - Drug developer Spark Therapeutics Inc said its lead experimental drug helped improve the vision of patients with a type of inherited eye disorder, in a late stage study.

The drug, SPK-RPE65, met the main goal of improving vision and sensitivity to light in patients who were previously at the risk of complete blindness, the company said on Monday.

(Reporting By Samantha Kareen Nair in Bengaluru; Editing by Savio D'Souza)

[© 2015 Thomson Reuters. All rights reserved.]

Copyright 2015 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.